



## ESC Declaration of Interest Report

### **2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death**

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the *ESC Declaration and Management of Conflict of Interest Policy*. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved by the ESC in July 2020.

The most up-to-date version of the policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Behr Elijah	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Boston Scientific : ICD implants</p>
	<p><b>2021</b></p> <p>Financial Declaration - Boston Scientific : ICD implants</p>
Blom Nico	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Charron Philippe	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : Cardiomyopathies - Amicus : Lysosomal diseases</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Head scientific committee of the association of patients: Ligue contre la Cardiomyopathie</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Charron Philippe	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Cardiomyopathies</li> <li>- Bristol Myers Squibb : Cardiomyopathies</li> <li>- Amicus : Lysosomal diseases</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Head scientific committee of the association of patients: Ligue contre la Cardiomyopathie</li> </ul>
	<p><b>2020</b></p> <p>Nothing to be declared</p>
Corrado Domenico	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2020</b></p> <p>Nothing to be declared</p>
Dagres Nikolaos	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2020</b></p> <p>Nothing to be declared</p>
de Chillou Christian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Honoraria</li> </ul>
	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
de Chillou Christian	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Honoraria</li> </ul>
De Riva Silva Marta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial fibrillation</li> </ul>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Eckardt Lars	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : speaker fees</li> <li>- Bayer : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Boston Scientific : speaker fees</li> <li>- Daiichi Sankyo : speaker fees</li> <li>- Medtronic : speaker fees</li> <li>- Novartis : speaker fees</li> <li>- Biotronik : speaker fees</li> <li>- Bristol Myers Squibb : speaker fees</li> <li>- Biosense Webster : speaker fees</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : travel and meeting support</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Eckardt Lars	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Boston Scientific : travel and meeting support</li> <li>- Medtronic : travel and meeting support</li> <li>- Biotronik : travel and meeting support</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Deutsche Forschungsgemeinschaft : Electrophysiology/Arrhythmia</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Lecture fees</li> <li>- Bayer : Lecture fees</li> <li>- Boston Scientific : Lecture fees</li> <li>- Daiichi Sankyo : Lecture fees</li> <li>- Medtronic : Lecture fees</li> <li>- Biotronik : Lecture fees</li> <li>- Sanofi Aventis : Lecture fees</li> <li>- Bristol Myers Squibb : Lecture fees</li> </ul>
Friede Tim	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Membership in Data Monitoring Committees</li> <li>- Genentech : Membership in Data Monitoring Committees</li> <li>- Roche Pharma : Membership in Data Monitoring Committees</li> <li>- Cardialysis : Membership in Data Monitoring Committees</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Friede Tim	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Enanta : Membership in Data Monitoring Committees</li> <li>- Dermira : Membership in Data Monitoring Committees</li> <li>- Sorin Group : Statistical consulting</li> <li>- Novartis : Statistical consulting including Data Monitoring Committees</li> <li>- Bayer AG : Statistical consulting including Data Monitoring Committees</li> <li>- Fresenius Kabi : Training in statistics</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Membership in Data Monitoring Committees</li> <li>- Genentech : Membership in Data Monitoring Committees</li> <li>- Roche Pharma : Membership in Data Monitoring Committees</li> <li>- Cardialysis : Membership in Data Monitoring Committees</li> <li>- Advanced Accelerator Applications : Membership in Data Monitoring Committees</li> <li>- Enanta : Membership in Data Monitoring Committees</li> <li>- Dermira : Membership in Data Monitoring Committees</li> <li>- IQVIA Ltd : Membership in Data Monitoring Committees</li> <li>- Labcorp Drug Development Inc. : Membership of Data Monitoring Committees</li> <li>- Minoryx : Statistical consulting</li> <li>- Relaxera Pharmazeutische Gesellschaft mbH &amp; Co. KG : Statistical consulting</li> <li>- Kyowa Kirin Inc. : Statistical consulting</li> <li>- Galapagos NV : Statistical consulting</li> <li>- Novartis : Statistical consulting including Data Monitoring Committees</li> <li>- Bayer AG : Statistical consulting including Data Monitoring Committees</li> <li>- Vifor International : Statistical consulting; Steering committee</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Friede Tim	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- CSL Behring : Statistical consulting; Steering committee</li> <li>- RECARDIO GmbH : Statistical consulting; Steering committee</li> <li>- Fresenius Kabi : Training in statistics</li> </ul>
Haugaa Kristina Hermann	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : speaker fees</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : speaker fee</li> <li>- Pfizer : speaker fee</li> </ul>
Hocini Meleze	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : research</li> <li>- Biosense Webster : research</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Lambiase Pier	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Arrhythmia mapping-speaker fees</li> <li>- Boston Scientific : ICDs and arrhythmias-Speaker fees</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lambiase Pier	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Arrhythmia Research</li> <li>- Boston Scientific : ICD and arrhythmia research</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Cardiomyopathy Association UK Advisory Board (Patient organisation)-no fee</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : ICDs</li> <li>- Abbott : mapping VT</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : VT mapping</li> </ul>
Marijon Eloi	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Sudden cardiac death (epidemiology and risk factors)</li> <li>- Medtronic : Sudden cardiac death (epidemiology and risk factors)</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Sudden cardiac death (epidemiology and risk factors)</li> </ul>



## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Marijon Eloi	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Medtronic : Sudden cardiac death (epidemiology and risk factors)</li> <li>- Zoll Medical : Sudden cardiac death (epidemiology and risk factors)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Microport : Sudden cardiac death</li> <li>- Boston Scientific : Sudden cardiac death (epidemiology and risk factors)</li> <li>- Medtronic : Sudden cardiac death (epidemiology and risk factors)</li> <li>- Biotronik : Sudden cardiac death (epidemiology and risk factors)</li> <li>- Medtronic Foundation : Sudden cardiac death (epidemiology and risk factors)</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Sudden death, arrhythmias and cardiac devices</li> <li>- Bayer : Sudden death, arrhythmias and cardiac devices</li> <li>- Boston Scientific : Sudden death, arrhythmias and cardiac devices</li> <li>- Medtronic : Sudden death, arrhythmias and cardiac devices</li> <li>- Zoll Medical : Sudden death, arrhythmias and cardiac devices</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Sudden death, arrhythmias and cardiac devices</li> <li>- Boston Scientific : Sudden death, arrhythmias and cardiac devices</li> <li>- Medtronic : Sudden death, arrhythmias and cardiac devices</li> <li>- Biotronik : Sudden death, arrhythmias and cardiac devices</li> <li>- Biosense Webster : Sudden death, arrhythmias and cardiac devices</li> <li>- Zoll Medical : Sudden death, arrhythmias and cardiac devices</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Marijon Eloi	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Microport : Sudden death, arrhythmias and cardiac devices</li> </ul>
Merino Jose Luis	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Atrial fibrillation and dronedarone</li> <li>- Boston Scientific : Catheter ablación, desfibrillators</li> <li>- Microport : Catheter ablation, defibrillators</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense : Catheter ablation</li> <li>- Abbott : Catheter ablation and Defibrillators</li> <li>- Boston Scientific : Catheter ablation and Defibrillators</li> <li>- Medtronic : Defibrillators</li> <li>- Biotronik : Defibrillators</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Atrial fibrillation ablation and Defibrillators</li> <li>- Daiichi Sankyo : Atrial fibrillation and Anticoagulation</li> <li>- Biotronik : Cardiac Resynchronization</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Atrial fibrillation and dronedarone</li> <li>- Microport : Catheter ablation</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Merino Jose Luis	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Medtronic : Pacemakers and Defibrillators</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Catheter ablation and Defibrillators</li> <li>- Boston Scientific : Defibrillators</li> <li>- Microport : Defibrillators</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Atrial fibrillation ablation and Defibrillators</li> <li>- Daiichi Sankyo : Atrial fibrillation and Anticoagulation</li> <li>- Biotronik : Cardiac Resynchronization</li> <li>- Milestone : Supraventricular tachycardia and Etripamil</li> </ul>
Peichl Petr	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : Consultation - catheter ablation</li> <li>- Medtronic : consultations</li> <li>- Abbott : consultations, lecturing - catheter ablation</li> <li>- Merck Sharp &amp; Dohme : lecturing</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Biotronik : Consultation - catheter ablation</li> <li>- Medtronic : consultations - catheter ablations</li> <li>- Abbott : consultations, lecturing - catheter ablation</li> <li>- Astra Zeneca : lecturing - catheter ablations</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Peichl Petr	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Biosense Webster : lecturing - catheter ablations</li> <li>- Promed : lecturing - catheter ablations</li> </ul>
Priori Silvia Giuliana	<p><b>2020</b></p> <p style="padding-left: 40px;">Nothing to be declared</p>
	<p><b>2021</b></p> <p style="padding-left: 40px;">Financial Declaration</p> <p style="padding-left: 40px;">Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- European Commission - : Grant reviewer: EIC and ERC Grants</li> </ul>
Reichlin Tobias	<p><b>2020</b></p> <p style="padding-left: 40px;">Financial Declaration</p> <p style="padding-left: 40px;">Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Leadless Pacing &amp; extracardiac ICD</li> </ul> <p style="padding-left: 40px;">Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Mapping System, Ablation Catheters, Pacemaker &amp; ICD's</li> <li>- Biotronik : Mapping System, Ablation Catheters, Pacemaker &amp; ICD's</li> <li>- Bayer : NOAC</li> <li>- Medtronic : Pacemaker &amp; ICD's</li> </ul> <p style="padding-left: 40px;">Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Mapping &amp; Ablation</li> <li>- Abbott/SJM : PM &amp; ICD</li> <li>- Medtronic : PM &amp; ICD, Ablation</li> <li>- Boston Scientific : PM &amp; ICD, Mapping &amp; Ablation</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Reichlin Tobias	<p><b>2020</b> - Biotronik : PM, ICD &amp; ICM</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Leadless Pacemaker, Diabetes, Ablation catheters</li> <li>- Biosense Webster : Mapping &amp; Ablation System</li> <li>- Boston Scientific : Mapping System, Ablation Catheters</li> <li>- Biotronik : Mapping System, Ablation Catheters, Pacemaker</li> <li>- Bayer : NOAC</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Mapping &amp; Ablation</li> <li>- Medtronic : PM &amp; ICD, Ablation</li> <li>- Boston Scientific : PM &amp; ICD, Mapping &amp; Ablation</li> <li>- Biotronik : PM, ICD &amp; ICM</li> </ul>
Schulz-Menger Jeanette	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Chemie AG : CMR</li> <li>- Bayer Healthcare : CMR</li> <li>- Circle institute : CMR</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CMR</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Schulz-Menger Jeanette	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : CMR</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Education - Circle institute</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Chemie AG : CMR</li> <li>- Circle institute : CMR</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CMR</li> <li>- Circle Cardiovascular Imaging, Inc : CMR</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Education - circle institute</li> </ul> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- SCMR</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sticherling Christian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation</li> <li>- Abbott : Ablation, ICD, Pacemaker</li> <li>- Microport : Defibrillators, Pacemaker</li> <li>- Boston Scientific : Defibrillators, Pacemaker, Ablation</li> <li>- Medtronic : Defibrillators, Pacemaker, Ablation</li> <li>- Biotronik : Defibrillators, Pacemaker, Ablation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : CRM</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Ablation, Loop recorder</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation</li> <li>- Abbott : Ablation, ICD, Pacemaker</li> <li>- Microport : Defibrillators, Pacemaker</li> <li>- Boston Scientific : Defibrillators, Pacemaker, Ablation</li> <li>- Medtronic : Defibrillators, Pacemaker, Ablation</li> <li>- Biotronik : Defibrillators, Pacemaker, Ablation</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sticherling Christian	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Biotronik : CRM</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Medtronic : Ablation, Loop recorder</p>
Tfelt-Hansen Jacob	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Abbott : ICD - Medtronic : ICD</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Leo Pharma : dermatology</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Danish heart foundation</p>
Tzeis Stylianos	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Abbott : Speaker fees, advisory board fees, honoraria - Bayer : Speaker fees, advisory board fees, honoraria</p>



## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Tzeis Stylianos	<b>2020</b> - Pfizer : Speaker fees, advisory board fees, honoraria - Biosense Webster : Speaker fees, advisory board fees, honoraria
	<b>2021</b> Financial Declaration - Abbott : Speaker fees, advisory board fees, honoraria - Bayer : Speaker fees, advisory board fees, honoraria - Pfizer : Speaker fees, advisory board fees, honoraria - Biosense Webster : Speaker fees, advisory board fees, honoraria
verstrael Axel	<b>2020</b> Nothing to be declared
	<b>2021</b> Nothing to be declared
Volterrani Maurizio	<b>2020</b> Nothing to be declared
	<b>2021</b> Nothing to be declared
Winkel Bo Gregers	<b>2020</b> Nothing to be declared
	<b>2021</b> Nothing to be declared
Zeppenfeld Katja	<b>2020</b> Financial Declaration  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Biosense Webster : Research electrophysiology

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Zeppenfeld Katja	<b>2021</b> Financial Declaration - Biosense Webster : Research electrophysiology

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Aboyans Victor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Astrazeneca : Diabetes</li> <li>- Boehringer Ingelheim : Diabetes</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of the French Society of Cardiology</li> </ul>
Al Saadi Ahmad Rasheed	<p><b>2021</b></p> <p>Nothing to be declared</p>
Aliyev Farid	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Allam Elsayed Lamyaa Elsayed	<b>2021</b>  Nothing to be declared
Arbelo Elena	<b>2021</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Atrial fibrillation
Arnar David O	<b>2021</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - DeCODE genetics : consultancy in cardiovascular genetics
Arribas Fernando	<b>2021</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Microport : Advisory Board - Bayer : Advisory Board / Speaker fee - Arrhythmia Network Technology SL / BAROSTIM : Advisory Board / Speaker fee - Abbott : Advisory Board, Education - Daiichi Sankyo : Speaker fee - Impulse Dynamics : Speaker fee  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Medtronic : Implantable Devices / Physiological pacing - Biotronik : Implantable Devices / Physiological pacing

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Arribas Fernando	<b>2021</b> - Abbott : Tachycardia Mapping and Ablation - Boston Scientific : Tachycardia Mapping and Ablation
Asteggiano Riccardo	<b>2021</b> Financial Declaration  Receipt of royalties for intellectual property.For yourself - Council of Cardio-Oncology ESC : cardio-oncology
Basso Cristina	<b>2021</b>  Nothing to be declared
Bauer Axel	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Daiichi Sankyo : PCI - Boston Scientific : TAVI  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Medtronic : Implantable Cardiac Monitors
Bertaglia Emanuele	<b>2021</b>  Nothing to be declared
Biering-Sorensen Tor	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Heart Failure - Novartis : Heart Failure - Sanofi Pasteur : Heart Failure

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Biering-Sorensen Tor	<p><b>2021</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Echocardiography</li> <li>- Sanofi Pasteur : Heart Failure</li> </ul>
Bini Roberto	<p><b>2021</b></p> <p>Nothing to be declared</p>
Blomstrom-Lundqvist Carina	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoaglation</li> <li>- Bayer : anticoagulation</li> <li>- Sanofi Aventis : anticoagulation</li> <li>- Johnson &amp; Johnson : atial fibrillation</li> <li>- Merck Sharp &amp; Dohme : atrial fibrillation</li> <li>- Philips : device infections</li> <li>- Boston Scientific : devices, atrial fibrillation ablation</li> <li>- Medtronic : devices, atrial fibrillation ablation</li> <li>- Orion : heart faliture</li> <li>- Cathprint : Medical technical equipments</li> </ul>
Borger Michael A	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Borger Michael A	<b>2021</b> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul>
Boskovic Aneta	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Bayer : Atrial fibrillation</li> <li>- Astra Zeneca : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> </ul>
Celutkiene Jelena	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul>
Christophides Theodoros	<b>2021</b>  Nothing to be declared
Cikes Maja	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- GE Healthcare : Cardiovascular ultrasound</li> <li>- Amicus Therapeutics : Fabry disease</li> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> <li>- Krka Pharma : Heart failure</li> <li>- Llvanova : Heart failure</li> <li>- Novartis : Heart failure, hyperlipidaemia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Cosyns Bernard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : unrestricted research grant in the field of interventional cardiology</li> </ul>
Cozma Dragos Constantin	<p><b>2021</b></p> <p>Nothing to be declared</p>



## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
David Lilia	<b>2021</b>  Nothing to be declared
Demircan Sabri	<b>2021</b>  Nothing to be declared
Dimmer Carlo	<b>2021</b>  Nothing to be declared
Duru Firat	<b>2021</b>  Financial Declaration  Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Abbott : Arrhythmia - Boston Scientific : Arrhythmia - Medtronic : Arrhythmia - Biotronik : Arrhythmia - Biosense Webster : Arrhythmia  Other Positions of Influence  Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of the Board of the Swiss Working Group on Pacemakers and Electrophysiology of the Swiss Society of Cardiology
Elezi Shpend	<b>2021</b>  Nothing to be declared

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Etsadashvili Kakhaber	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : DOACs</li> <li>- Servier : Hypertension</li> </ul>
Falk Volkmar	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> <li>- Boston Scientific : Study</li> <li>- Biotronik : Study</li> <li>- Liva Nova : Study</li> </ul>
Fauchier Laurent	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Healthcare</li> <li>- Bayer : Healthcare</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- Novo-Nordisk : Healthcare</li> <li>- Zoll Medical : Healthcare</li> <li>- XO : Healthcare</li> </ul>
Galvin Joseph	<p><b>2021</b></p> <p>Financial Declaration</p> <p style="padding-left: 40px;">Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Catheter ablation</li> </ul> <p>Other Positions of Influence</p> <p style="padding-left: 40px;">Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <ul style="list-style-type: none"> <li>- I work as a cardiologist in the Mater University and Private Hospitals in Dublin</li> </ul>
Gatzoulis Konstantinos	<p><b>2021</b></p> <p>Financial Declaration</p> <p style="padding-left: 40px;">Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Hippokrateion Hospital : Cardiology - Electrophysiology</li> </ul> <p style="padding-left: 40px;">Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Private practice : Cardiology and Cardiac Electrophysiology</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gatzoulis Konstantinos	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself - Raycap supporting a current multicenter prospective trial ( Reconsider study)</p>
Geller Laszlo Alajos	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Abbott : Electrophysiology - Medtronic : Electrophysiology - Biotronik : Electrophysiology - Johnson &amp; Johnson : Electrophysiology</p>
Golukhova Elena	<p><b>2021</b></p> <p>Nothing to be declared</p>
Gorenek Bulent	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself - Astra Zeneca : ACS - Sanofi Aventis : ACS - Roche Diagnostics : ACS - Bayer : Atrial Fibrillation - Sandoz : Atrial fibrillation - Sanovel : Atrial fibrillation - Daiichi Sankyo : Atrial Fibrillation, ACS</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gorenek Bulent	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Deva : Hypertension</li> </ul>
Haim Mordechai	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : advisory board fees</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Cardiokol : AF SCREENING</li> <li>- Biotronik : CRT RESEARCH BIOSTREAM</li> </ul>
Halvorsen Sigrun	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation -speaker fee</li> <li>- Bristol Myers Squibb : Anticoagulation- speaker fee</li> <li>- Novartis : heart failure - speaker fee</li> </ul>
Hansen Jim	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation of ventricular tachycardia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Cryoballoon ablation training</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Hansen Jim	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Biosense Webster : VT</p>
Hatala Robert	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : antihypertensive therapy</li> <li>- Pfizer : antithrombotic therapy</li> <li>- Merck Sharp &amp; Dohme : antithrombotic therapy</li> <li>- Organon : antithrombotic therapy</li> <li>- Novo-Nordisk : atherosclerosis, diabetes</li> <li>- Medtronic : atrial fibrillation</li> <li>- AbbVie : coronary heart disease</li> <li>- Abbott : device therapy</li> <li>- AOP Orphan Pharmaceuticals : drug therapy</li> <li>- Novartis : heart failure</li> <li>- Amgen : myocardial infarction</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Medtronic : CRM</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Heidbuchel Hein	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- BMS : Anticoagulation</li> <li>- Abbott : Arrhythmia therapy</li> <li>- Biotronik : Arrhythmia therapy</li> <li>- Medscape : Education</li> <li>- Springer Healthcare Ltd. : Education</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Biosense-Webster : Ablation</li> <li>- Fibrichk-Qompium : AF Screening</li> <li>- Biotronik : CIED</li> <li>- Abbott : CIED &amp; structural heart</li> <li>- Boston Scientific : CIED &amp; structural heart</li> <li>- Medtronic : CIED &amp; structural heart</li> <li>- Bayer : CV drugs</li> <li>- Boehringer-Ingelheim : CV drugs</li> <li>- Daiichi Sankyo : CV drugs</li> <li>- Pfizer/BMS : CV drugs</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Hlivak Peter	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : antihypertensive therapy</li> <li>- Novo-Nordisk : hypoglycemic therapy in CVD</li> <li>- Boehringer-Ingelheim : SPAF - thromboprophylaxis in AF</li> <li>- Pfizer : SPAF - thromboprophylaxis in AF</li> <li>- Bayer : SPAF - thromboprophylaxis in AF, thromoprofylaxis in CAD</li> </ul>
Junttila Juhani	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation/ lectures</li> <li>- Merck Sharp &amp; Dohme : anticoagulation/advisory board</li> <li>- Boehringer-Ingelheim : diabetes, cardiovascular disease/advisory board, lectures</li> <li>- Sanofi Aventis : diabetes, cardiovascular disease/lecture</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Editorial board membership Heart Rhythm journal</li> </ul>



## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kaab Stefan	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : oral anticoagulation, congestive heart failure</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Delegate of Bayerische Landesärztekammer (BLÄK)</li> </ul>
Kalejs Oskars	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Cardiovascula Pharmacotherapy</li> <li>- Boehringer-Ingelheim : Cardiovascular Pharmacotherapy</li> <li>- Pfizer : Cardiovascular Pharmacotherapy</li> <li>- Berlin Menarini : Cardiovascular Pharmacotherapy</li> <li>- Bayer AG : Cardiovascular Pharmacotherapy.</li> </ul>
Kampus Priit	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Home remote monitoring</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kautzner Josef	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : catheters, devices</li> <li>- AFFERA : catheters, mapping system</li> <li>- Biosense Webster : catheters, mapping systems</li> <li>- St Jude Medical - Abbott : devices, catheters, mapping systems, valves</li> <li>- Medtronic : devices, catheters, valves</li> <li>- Bayer : drugs</li> <li>- Boehringer-Ingelheim : drugs</li> <li>- Pfizer : drugs</li> <li>- Mylan : drugs</li> <li>- Promed Cs : drugs</li> <li>- CathVision : recording system</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : catheters, devices - clinical studies, educational events</li> <li>- AFFERA : catheters, mapping system - clinical studies</li> <li>- Abbott -SJM : catheters, mapping system, clinical studies</li> <li>- CathVision : recording system</li> </ul>
Kerimkulova Alina	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kichou Brahim	<p><b>2021</b></p> <p>Nothing to be declared</p>
Kirchhof Paulus	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular</li> <li>- Medtronic : cardiovascular</li> <li>- Philips : cardiovascular</li> <li>- Sanofi Aventis : cardiovascular</li> <li>- Roche Diagnostics : cardiovascular</li> <li>- Johnson&amp;Johnson : cardiovascular</li> <li>- Astra Zeneca : cardiovascular</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : cardiovascular</li> <li>- Daiichi Sankyo : cardiovascular</li> <li>- Sanofi Aventis : cardiovascular</li> <li>- British Heart Foundation : cardiovascular</li> <li>- BMS / Pfizer alliance : cardiovascular</li> <li>- Leducq Foundation : cardiovascular</li> <li>- European Union horizon2020 : cardiovascular</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular</li> <li>- UK Medical Research Council : cardiovascular</li> <li>- NIHR (UK National Institute of Health Research) : cardiovascular</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself</p> <ul style="list-style-type: none"> <li>- Education - AFNET (chair of board). There is no direct financial interest and my work is not remunerated (volunteer work). AFNET cooperates with ESC on conferences, education, and clinical trials. I still would like to declare this relationship.</li> </ul> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of the advisory board, Deutsche Herzstiftung</li> </ul>
Konradi Aleksandra	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertsniion</li> </ul>
Koskinas Konstantinos	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> <li>- MyoKardia : Trial Advisory Board</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> <li>- Protherics Medicines Development : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> <li>- Sanofi Aventis : Speaker fee</li> <li>- Bayer AG : Speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Amgen : Research grant</li> <li>- Bayer AG : Research Grant</li> </ul>
Leclercq Christophe	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : devices</li> <li>- Medtronic : devices</li> <li>- Sorin Group : Devices</li> <li>- Biotronik : devices</li> </ul>
Lewis Basil S	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Idorsia : Antithrombotics</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
Linhart Ales	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Avrobio : Faby disease</li> <li>- Novartis : Heart failure</li> </ul>
Lochen Maja-Lisa	<p><b>2021</b></p> <p>Nothing to be declared</p>
Lund Lars	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Bayer : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lund Lars	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Heart failure</li> <li>- Vifor International : Heart failure</li> <li>- Merck Sharp &amp; Dohme : Heart failure</li> <li>- Medscape : Heart failure</li> <li>- Astrazeneca : Heart failure</li> <li>- Myocardia : Heart failure</li> <li>- Lexicon : Heart failure</li> <li>- Pharmacosmos : Heart failure</li> <li>- Radcliffe : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Boston Scientific : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Vifor International : Heart failure</li> </ul>
Maass Alexander	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : critical event committee</li> </ul>



## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Martirosyan Mihran	<p><b>2021</b></p> <p>Nothing to be declared</p>
Metzner Andreas	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Speaker fees</li> </ul>
Milicic Davor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Antidiabetics</li> <li>- Alcaloid AD Skopje : Antihypertensive medications</li> <li>- PLIVA : Antihypertensive medications</li> <li>- Krka Pharma : Antihypertensives</li> <li>- Astra Zeneca : Antithrombotics in ACS</li> <li>- Novartis : ARNI</li> <li>- Roche Diagnostics : Biomarkers</li> <li>- Abbott : LVAD</li> <li>- Servier : Microvascular angina</li> <li>- Bayer : NOACs</li> <li>- Pfizer : NOACs</li> <li>- Boehringer-Ingelheim : NOACs, SGLT-2 inhibitors</li> <li>- Amgen : PCSK-9 inhibitors</li> <li>- Sanofi Aventis : PCSK-9 inhibitors</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself  - I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Mitkowski Przemyslaw Piotr	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself  - Boston Scientific : CIED  - Medtronic : CIED  - Biotronik : CIED  - Abbott Vascular : CIED  - Astra Zeneca : Drugs Flosins, P2Y12  - Novartis : Drugs HF, ARNI, inclisiran  - Servier : Drugs HF, Hypertension  - Sanofi Aventis : Drugs PSCK9 inhib  - Gedeon Richter : Drugs, spironolacton  - Hammermed : Lead Extraction  - Boehringer-Ingelheim : NOAC, Flosins</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mitekowski Przemyslaw Piotr	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Pfizer : NOACs</li> <li>- Bayer Healthcare : NOACs</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> <li>- Abbott Vascular : CIED</li> <li>- Opera : CIED, hypertension</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Servier : Drugs HF, hypertension</li> <li>- Pfizer : NOACs</li> <li>- Boehringer-Ingelheim : NOACs, SGLT2i</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> <li>- Abbott Vascular : CIED</li> <li>- Opera : CIED, hypertension</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : CIED</li> <li>- Biotronik : CIED</li> <li>- Abbott Vascular : CIED</li> <li>- Opera : CIED hypertension</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mitkowski Przemyslaw Piotr	<p><b>2021</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Pariiametary group for cardiology (as an Polish Cardiac Society representative)</p>
Mjølstad Ole Christian	<p><b>2021</b></p> <p>Nothing to be declared</p>
Moustaghfir Abdelhamid	<p><b>2021</b></p> <p>Nothing to be declared</p>
Naser Nabil	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Inclisiran for treatment of dyslipidemia</p>
Nielsen Jens Cosedis	<p><b>2021</b></p> <p>Nothing to be declared</p>
Norekval Tone Merete	<p><b>2021</b></p> <p>Nothing to be declared</p>
Ouali Sana	<p><b>2021</b></p> <p>Nothing to be declared</p>
Pappone Carlo	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biotronik : Arrhythmias - Biosense Webster : Arrhythmias</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Parreira Ana Leonor	<p><b>2021</b></p> <p>Nothing to be declared</p>
Patten Monica	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Alnylam : Amyloidosis</li> <li>- Amicus Therapeutics : Fabry Disease</li> <li>- Bristol Myers Squibb : Hypertrophic Cardiomyopathy</li> <li>- Takeda Pharmaceuticals : Morbus Fabry</li> <li>- Sanofi/Genezyme : Morbus Fabry</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Hypertrophic Cardiomyopathy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Takeda Pharmaceuticals : Fabry Disease</li> </ul>
Perez Castellano Nicasio	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : Ablation</li> <li>- Abbott : CIED</li> <li>- Boston Scientific : CIED</li> <li>- Microport : CIED</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Pernat Andrej	<p><b>2021</b></p> <p>Nothing to be declared</p>
Platonov Pyotr	<p><b>2021</b></p> <p>Nothing to be declared</p>
Poposka Lidija	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Alkaloid Skopje : CVD prevention</li> <li>- Bayer : NOAC</li> <li>- Pfizer : NOAC</li> </ul>
Prescott Eva	<p><b>2021</b></p> <p>Nothing to be declared</p>
Puodziukynas Aras	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : NOACs in patients with atrial fibrillation</li> <li>- Pfizer : NOACs in patients with atrial fibrillation</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : NOACs in patients with atrial fibrillation</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : ACC Congress 2021 Registration Fee. NOACs in patients with atrial fibrillation</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

<b>Expert</b>	<b>Type of Relationship with Industry</b>
Puodziukynas Aras	<b>2021</b> - Bayer : ESC CONGRESS 2021 Registration fee. NOACs in patients with atrial fibrillation
Rabah Ali	<b>2021</b> Nothing to be declared
Rakisheva Amina	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Bayer : Atrial Fibrillatuion - Novartis : Heart Failure
Remme Carol Ann	<b>2021</b> Nothing to be declared
Roca Luque Ivo	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Abbott : Arrhythmia
Sammut Mark	<b>2021</b> Financial Declaration  Travel and meeting support from healthcare industry, independent of the above activities.For yourself - Medtronic : Devices and ablation
Sarkozy Andrea	<b>2021</b> Financial Declaration  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Catheter ablation of atrial fibrillation and SVT

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Scherr Daniel	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Speaker fee</li> <li>- Daiichi Sankyo : Speaker fee</li> <li>- Medtronic : Speaker fee</li> <li>- Pfizer : Speaker fee</li> <li>- Biotronik : Speaker fee</li> <li>- Bayer Healthcare : Speaker fee</li> <li>- Zoll Medical : Speaker fee</li> </ul>
Shalghanov Tchavdar	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : investigator - dapagliflozin in heart failure</li> <li>- Bayer : speaker/moderator fees</li> </ul>
Sitges Marta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul>



## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2021</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Rovi : Heart Failure</li> <li>- Amgen : Hypercholesterolemia</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>
Slade Alistair Kenneth Bannerman	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Advisory Board on Medical Education</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- President British Heart Rhythm Society (no payment)</li> </ul>
Steven Daniel	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : EP</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Steven Daniel	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Boston Scientific : EP</li> <li>- Johnson &amp; Johnson : EP</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : EP</li> <li>- Johnson &amp; Johnson : EP</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : EP</li> </ul>
Stojkovic Sinisa	<p><b>2021</b></p> <p>Nothing to be declared</p>
Syhov Oleg	<p><b>2021</b></p> <p>Nothing to be declared</p>
Touyz Rhian	<p><b>2021</b></p> <p>Nothing to be declared</p>
van Mieghem Nicolas	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Biotronik : ACS</li> <li>- Boston Scientific : Complex PCI and structural heart interventions/TAVI</li> <li>- Pie Medical : Imaging</li> <li>- Daiichi Sankyo : NOAC and TAVI</li> </ul>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Velagic Vedran	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Biosense Webster : proctoring</li> <li>- Bayer : speaker fee</li> <li>- Pfizer : speaker fee</li> <li>- Krka Pharma : speaker fee</li> <li>- PLIVA : speaker fee</li> <li>- Astra Zeneca : speaker fees</li> <li>- Berlin Menarini : speaker fees</li> <li>- Medtronic : speaker fees, proctoring</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Teva Pharmaceutical Industries : Congress - travel expenses</li> </ul>
Viskin Samuel	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- European Scientific Advisory Board, Boston Scientific : European Scientific Advisory Board</li> </ul>
Volders Paul	<p><b>2021</b></p> <p>Nothing to be declared</p>

## 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Willems Rik	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : AF</li> <li>- Boehringer-Ingelheim : AF</li> <li>- Daiichi Sankyo : AF</li> <li>- Pfizer : AF</li> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Medtronic : CRM</li> <li>- Biotronik : CRM</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : CRM</li> <li>- Boston Scientific : CRM</li> <li>- Medtronic : CRM</li> <li>- Biotronik : CRM</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Aboyans Victor	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Bristol Myers Squibb : Antithrombotic therapies</li> <li>- Astrazeneca : Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Peripheral Artery Disease</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Novo-Nordisk : Diabetes</li> <li>- Astrazeneca : Diabetes</li> <li>- Boehringer Ingelheim : Diabetes</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- Member of the French Society of Cardiology</li> </ul>
Antoniou Sotiris	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees for education - AF</li> <li>- Bayer AG : speaker fees for education - AF</li> <li>- Daiichi Sankyo : speaker fees for education -AF</li> <li>- Astra Zeneca : speaker fees for education - CVD</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Joint working initiative on improving CV care</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Pfizer : speaker fees for education - AF - Bayer AG : speaker fees for education - AF - Daiichi Sankyo : speaker fees for education -AF - Astra Zeneca : speaker fees for education - CVD - Boehringer-Ingelheim : speaker fees for education - CVD</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself - Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Arrhythmia alliance medical advisory panel</p>
Arbelo Elena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Biosense Webster : Atrial fibrillation</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Arbelo Elena	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Atrial fibrillation</li> </ul>
Asteggiano Riccardo	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property.For yourself</p> <ul style="list-style-type: none"> <li>- Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Council of Cardio-Oncology ESC : cardio-oncology</li> </ul>
Baigent Colin	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Cardiovascular and renal disease</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Renal disease</li> </ul>
Baumbach Andreas	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Pharmacology</li> <li>- CERC : Research Organisation: Events Committees</li> <li>- Abbot Vascular : Stents</li> <li>- Microport : Stents</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Baumbach Andreas	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Sinomed : Stents</li> <li>- Venus Medtech : Valves, CEP</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet</li> <li>- Faraday : Infarct size reduction</li> <li>- Microport : Stents</li> <li>- Sinomed : Stents</li> <li>- Medtronic : Valves</li> <li>- Pi-Cardia : Valves</li> </ul> <p>Research funding (personal) from healthcare industry.For yourself</p> <ul style="list-style-type: none"> <li>- Abbot Vascular : OCT</li> </ul>
Borger Michael A	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Borger Michael A	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Medtronic : heart valve therapy</li> </ul>
Celutkiene Jelena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Amgen : heart failure</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : heart failure</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation, amyloidosis</li> <li>- Astra Zeneca : coronary heart disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Orion : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure</li> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- GE Healthcare : Cardiovascular ultrasound</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Amicus Therapeutics : Fabry disease</li> <li>- Astra Zeneca : Heart failure</li> <li>- Bayer : Heart failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> <li>- Krka Pharma : Heart failure</li> <li>- Llvanova : Heart failure</li> <li>- Novartis : Heart failure, hyperlipidaemia</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Pfizer : Amyloidosis</li> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Collet Jean-Philippe	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Astra Zeneca : Post-PCI antiplatelet treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p><b>2020</b> - Bristol Myers Squibb : Post-TAVR antithrombotic treatment</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : post PCI antithrombotic therapy</li> <li>- Pfizer : POST PCI ANTITHROMBOTIC THERAPY</li> <li>- Terumo Inc : POST PCI ANTITHROMBOTIC THERAPY</li> <li>- Bristol Myers Squibb : Post-TAVI antithrombotic treatments</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Medtronic : post tavi antithrombotic therapy</li> <li>- Bristol Myers Squibb : post-tavi antithrombotic therapy</li> </ul>
Falk Volkmar	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> <li>- Boston Scientific : Study</li> <li>- Biotronik : Study</li> <li>- Liva Nova : Study</li> </ul>
Fauchier Laurent	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- XO : Healthcare</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Healthcare</li> <li>- Bayer : Healthcare</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- Novo-Nordisk : Healthcare</li> <li>- Zoll Medical : Healthcare</li> <li>- XO : Healthcare</li> </ul>
Gale Christopher Peter	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acs hf</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : af</li> <li>- Abbott : diabetes</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : ACS</li> <li>- Chiesi Pharma : ACS</li> <li>- Astra Zeneca : ACS Hf</li> <li>- Boehringer-Ingelheim : AF</li> <li>- Daiichi Sankyo : AF</li> <li>- Menarini : CAD</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Bayer : CVD</li> <li>- Zydus : CVD</li> <li>- Oxford University Press : EHJQCCO</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : AF</li> <li>- Abbott : Diabetes</li> <li>- European Society of Cardiology : EuroHeart</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.For yourself</p> <ul style="list-style-type: none"> <li>- Wondrmedical</li> </ul>
Halvorsen Sigrun	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Sanofi Aventis : Lipidlowering</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart failure</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulation -speaker fee</li> <li>- Bristol Myers Squibb : Anticoagulation- speaker fee</li> <li>- Novartis : heart failure - speaker fee</li> </ul>
Iung Bernard	<p><b>2020</b></p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p><b>2020</b></p> <p>Nothing to be declared</p> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : heart failure</li> </ul>
Konradi Aleksandra	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<b>2020</b> - Servier : hypertsniion
	<b>2021</b> Financial Declaration - Novartis : hypertension - Krka Pharma : hypertension - Gedeon Richter : hypertension - Servier : hypertsniion
Koskinas Konstantinos	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Cardiology - Daiichi Sankyo : Cardiology  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Cardiology
	<b>2021</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Amgen : Cardiology - Daiichi Sankyo : Cardiology  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Novartis : Cardiology

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> <li>- MyoKardia : Trial Advisory Board</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> <li>- Protherics Medicines Development : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>
Landmesser Ulf	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory Board fee</li> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Bayer AG : Research Grant</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> <li>- Sanofi Aventis : Speaker fee</li> <li>- Bayer AG : Speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Amgen : Research grant</li> <li>- Bayer AG : Research Grant</li> </ul>
Lewis Basil S	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Vifor International : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Idorsia : Antithrombotics</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
Linhart Ales	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> </ul>
	<p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Linhart Ales	<p><b>2021</b></p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> <li>- Avrobio : Faby disease</li> <li>- Novartis : Heart failure</li> </ul>
Lochen Maja-Lisa	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
Mindham Richard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Imperial College, London : 3 honoraria totalling GB£500/€550, passed in full to UK charity, CardiomyopathyUK. There will be no more honoraria.</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself</p> <ul style="list-style-type: none"> <li>- I support actively the British charity CardiomyopathyUK and make a monthly payment to support their activites. I also passed the three honoraria in 2A to CardiomyopathyUK, in full.</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself</p> <ul style="list-style-type: none"> <li>- Re item 7A: I have shares which are held inside and outside of a pension. I am unaware of what the shares are as they are all managed by a portfolio manager. Consequently I do not know whether I hold any shares in healthcare or healthcare-related companies, or in media or education companies.</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
Nielsen Jens Cosedis	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself - Member of Danish Heart Foundation</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.For yourself - I received institutional research grants from the Novo Nordisk Foundation</p> <hr/> <p><b>2021</b></p> <p>Nothing to be declared</p>
Petersen Steffen Erhard	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself            - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself            - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself            - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.For yourself            - Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.For yourself            - Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</p>
Prescott Eva	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Rakisheva Amina	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillatuion</li> <li>- Novartis : Heart Failure</li> </ul>
Sitges Marta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2021.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2021</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.For yourself</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).For yourself</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Rovi : Heart Failure</li> <li>- Amgen : Hypercholesterolemia</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>
Touyz Rhian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.For yourself</p> <ul style="list-style-type: none"> <li>- Novartis : Consultancy-expert opinion</li> </ul> <hr style="border-top: 1px dashed black;"/> <p><b>2021</b></p> <p>Nothing to be declared</p>